Payment overview · 2025
General Payments
$1,068.93
55 reported records · 16 companies
Healthcare provider profile · identity verified
Tram Ho, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1649350901
Verified facts
What the public records show
CMS Open Payments records show Tram Ho, MD received $1,068.93 in general payments during 2025 across 55 reported records.
Amgen Inc. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Shingrix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $266.57 | 24.9% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.70 | 12.7% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $115.29 | 10.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.18 | 9.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.87 | 6.7% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$62.43 | 5.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.69 | 4.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.78 | 4.6% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $43.79 | 4.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.89 | 4.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.48 | 2.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.05 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.85 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.56 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.71 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.09 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,068.93 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $146.98 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $146.98 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.70 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $115.29 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $95.89 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $93.72 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.87 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $62.92 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $62.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.69 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.78 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.78 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.89 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 322 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 40 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 260 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 460 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
196 | 123 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
322 | 94 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
260 | 67 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
260 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
139 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
460 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
59 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2671 | 828 |
| Amlodipine Besylate | Amlodipine Besylate | 1452 | 457 |
| Losartan Potassium | Losartan Potassium | 1425 | 444 |
| Metformin Hcl | Metformin Hcl | 1112 | 358 |
| Famotidine | Famotidine | 655 | 241 |
| Gabapentin | Gabapentin | 607 | 211 |
| Alendronate Sodium | Alendronate Sodium | 463 | 162 |
| Ozempic | Semaglutide | 460 | 86 |
| Donepezil Hcl | Donepezil Hcl | 432 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 146 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 383 | 151 |
| Fluticasone Propionate | Fluticasone Propionate | 356 | 131 |
| Carvedilol | Carvedilol | 345 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 344 | 105 |
| Farxiga | Dapagliflozin Propanediol | 322 | 94 |
| Simvastatin | Simvastatin | 299 | 95 |
| Glipizide Er | Glipizide | 292 | 99 |
| Memantine Hcl | Memantine Hcl | 288 | 98 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 281 | 160 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 89 |
| Lisinopril | Lisinopril | 271 | 89 |
| Vascepa | Icosapent Ethyl | 264 | 83 |
| Jardiance | Empagliflozin | 260 | 67 |
| Montelukast Sodium | Montelukast Sodium | 244 | 84 |
| Pregabalin | Pregabalin | 235 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 234 | 108 |
| Tramadol Hcl | Tramadol Hcl | 229 | 82 |
| Allopurinol | Allopurinol | 222 | 81 |
| Omeprazole | Omeprazole | 214 | 84 |
| Mirtazapine | Mirtazapine | 207 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 100 |
| Prolia | Denosumab | 196 | 123 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 189 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 53 |
| Azelastine Hcl | Azelastine Hcl | 160 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 57 |
| Nifedipine Er | Nifedipine | 150 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 56 |
| Mometasone Furoate | Mometasone Furoate | 146 | 62 |
| Furosemide | Furosemide | 143 | 57 |
| Azithromycin | Azithromycin | 141 | 123 |
| Trulicity | Dulaglutide | 139 | 22 |
| Meclizine Hcl | Meclizine Hcl | 133 | 69 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 126 | 112 |
| Methylprednisolone | Methylprednisolone | 122 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 42 |
| Trazodone Hcl | Trazodone Hcl | 113 | 50 |
| Sertraline Hcl | Sertraline Hcl | 110 | 42 |
| Loperamide | Loperamide Hcl | 105 | 92 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 30 |
| Januvia | Sitagliptin Phosphate | 95 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 33 |
| Ammonium Lactate | Ammonium Lactate | 87 | 38 |
| Myrbetriq | Mirabegron | 86 | 23 |
| Ezetimibe | Ezetimibe | 85 | 28 |
| Fenofibrate | Fenofibrate,micronized | 85 | 27 |
| Metformin Hcl Er | Metformin Hcl | 82 | 34 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 76 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 23 |
| Finasteride | Finasteride | 71 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 16 |
| Enalapril Maleate | Enalapril Maleate | 65 | 19 |
| Fenofibrate | Fenofibrate | 65 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 59 | 59 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 59 | 19 |
| Vemlidy | Tenofovir Alafenamide | 59 | suppressed |
| Celecoxib | Celecoxib | 58 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 22 |
| Eliquis | Apixaban | 57 | 19 |
| Glimepiride | Glimepiride | 57 | 18 |
| Glipizide | Glipizide | 57 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 26 |
| Estradiol | Estradiol | 54 | 28 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 53 | 17 |
| Alprazolam | Alprazolam | 52 | 18 |
| Fluocinonide | Fluocinonide | 52 | 27 |
| Ketoconazole | Ketoconazole | 52 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 48 | 28 |
| Clonidine Hcl | Clonidine Hcl | 48 | 27 |
| Meloxicam | Meloxicam | 48 | 29 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 47 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 23 |
| Tradjenta | Linagliptin | 45 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 14 |
| Baclofen | Baclofen | 42 | 18 |
| Proctozone-Hc | Hydrocortisone | 42 | 21 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 42 | 17 |
| Gemtesa | Vibegron | 40 | 11 |
| Atenolol | Atenolol | 38 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 23 |
| Levemir Flextouch | Insulin Detemir | 33 | suppressed |
| Valsartan | Valsartan | 33 | 11 |
| Ibuprofen | Ibuprofen | 32 | 26 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Prednisone | Prednisone | 31 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 19 |
| Potassium Chloride | Potassium Chloride | 28 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 26 | 11 |
| Methimazole | Methimazole | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | 11 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Hydrocortisone | Hydrocortisone | 24 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 18 |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Risperidone | Risperidone | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Mupirocin | Mupirocin | 19 | 12 |
| Naproxen | Naproxen | 19 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Entecavir | Entecavir | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Colchicine | Colchicine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,068.93 · 55 records | Amgen Inc. | AREXVY, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, KRYSTEXXA, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SHINGRIX, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error